AbbVie receives EU approval for Aquipta (atogepant) as a treatment for migraine
The European Commission has approved AbbVie's atogepant under the brand name Aquipta for treating migraines, with or without aura. The decision was based on phase 3 trial results showing statistically significant pain freedom.
Tickers: $ABBV